Coarse Particle Mass Deposition from Trimbow MDI and Trelegy DPI: In Vitro Comparison and Implications for Oropharyngeal and Oral Side Effects (ERS 2026) - May 30, 2026 - Abstract #PA2574; Pres time: Sep 7, 2026; 08:00 AM - 09:30 AM; Location: PS-14; Board Number: 13; "These in vitro data provide guidance to clinicians that pairing the AeroChamber Plus Flow-Vu* spacer with a Trimbow MDI minimizes the CPM, the fraction associated with oropharyngeal deposition. By retaining the CPM in the chamber, the spacer significantly reduces oropharyngeal deposition (by ca. 96%), thereby lowering local oral medical and dental health risks."
Adverse events • Preclinical • Asthma • Immunology • Respiratory Diseases • Xerostomia
|
|
M. Nagel; Canada; R. Ali; J. Suggett
|